BRIAN CHEN: Open Payments
NPI 1629726500 · DUARTE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 29 payments from 11 companies in 2025. Trend: 2023 $313 · 2024 $505 · 2025 $899
Food & beverage: $759Education: $140
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 11 | $328 |
| Daiichi Sankyo Inc. | 7 | $187 |
| Melinta Therapeutics, LLC | 2 | $65 |
| GlaxoSmithKline, LLC. | 2 | $64 |
| E.R. Squibb & Sons, L.L.C. | 1 | $62 |
| GENZYME CORPORATION | 1 | $55 |
| PFIZER INC. | 1 | $38 |
| Alexion Pharmaceuticals, Inc. | 1 | $37 |
| Syndax Pharmaceuticals, Inc. | 1 | $30 |
| Eisai Inc. | 1 | $18 |
Products named: Vanflyta, Cresemba, Rezzayo, BLENREP, BREYANZI, Vyloy, WAYRILZ, Xospata.
Industry payments across CA — which companies pay providers there.
